Compare · BIO vs RVTY
BIO vs RVTY
Side-by-side comparison of Bio-Rad Laboratories Inc. (BIO) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIO and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $13.93B, about 1.3x BIO ($10.44B).
- Over the past year, BIO is up 31.9% and RVTY is up 36.7% - RVTY leads by 4.8 points.
- RVTY has been more active in the news (6 items in the past 4 weeks vs 2 for BIO).
- RVTY has more recent analyst coverage (20 ratings vs 12 for BIO).
- Company
- Bio-Rad Laboratories Inc.
- Revvity Inc.
- Price
- $390.39+2.45%
- $124.78+1.46%
- Market cap
- $10.44B
- $13.93B
- 1M return
- +23.48%
- +15.48%
- 1Y return
- +31.87%
- +36.67%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 1980
- News (4w)
- 2
- 6
- Recent ratings
- 12
- 20
Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Latest BIO
- IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
- Bio-Rad Reports Second-Quarter 2026 Financial Results
- Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026
- RBC Capital Mkts resumed coverage on Bio-Rad Labs with a new price target
- Bio-Rad to Participate in Upcoming Investor Conferences
- Bio-Rad Reports First-Quarter 2026 Financial Results
- Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
- Bio-Rad Labs downgraded by Citigroup with a new price target
- Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
- Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026
Latest RVTY
- Director Michas Alexis P gifted 285 shares (SEC Form 4)
- Officer Goldberg Joel S gifted 27,785 shares and received a gift of 27,785 shares, decreasing direct ownership by 67% to 13,729 units (SEC Form 4)
- Officer Singh Prahlad R. gifted 67,286 shares and received a gift of 67,286 shares, decreasing direct ownership by 59% to 46,026 units (SEC Form 4)
- SEC Form 10-Q filed by Revvity Inc.
- Revvity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Revvity Announces Financial Results for the Second Quarter of 2026
- Revvity Board Declares Quarterly Dividend
- Vice President and CAO Gonzales Anita sold $9,306 worth of shares (85 units at $109.48) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 7,201 units (SEC Form 4)
- Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure
- Revvity to Hold Earnings Call on Tuesday, August 4, 2026